INCY

In the past six months, Incyte's stock has experienced significant movement due to several key events. As of May 8, 2026, the stock has seen a 63.69% total shareholder return over the past year. On May 1, 2026, Incyte announced FDA approval of Jakafi XR™ for myelofibrosis, polycythemia vera, and graft-versus-host disease. On April 28, 2026, Incyte reported strong first-quarter 2026 financial results, with total net sales reaching $1.27 billion and adjusted EPS of $1.81, reaffirming its full-year 2026 guidance. On April 28, 2026, Suketu (Suky) Upadhyay was appointed as Chief Financial Officer, effective May 4, 2026. On March 25, 2026, Incyte announced executive leadership appointments. On March 28, 2026, Incyte announced positive 54-week late-breaking data for Povorcitinib in Hidradenitis Suppurativa. In January 2026, positive tafasitamab data was shared. The stock was up approximately 43% over the past year as of January 2, 2026. In May 2024, Incyte acquired Escient Pharmaceuticals for $750 million, adding two oral drug candidates for inflammatory diseases. In May 2024, Incyte expanded its presence in Delaware with the acquisition of two office buildings in Wilmington.